Jean Bergeron is a physician acting as consultant and clinical scientist at the, Endocrinology and Nephrology Research Unit, Centre de recherche du CHU de Québec – Université Laval, as well as Professor at the Molecular Biology, Medical Biochimistry and Pathology Department, Faculty of Medicine, Laval University. He is member of the Medical Biochimistry Unit (Department of Laboratory Medicine) and chief of the Lipid clinic (Department of Medicine) of the CHU de Québec-Université Laval. He is also Secretary for the Société Québécoise de Lipidologie, Nutrition et Métabolisme (SQLNM), a scientific society from which he received in 2012 a recognition award, Le prix des Fondateurs Jean Davignon et Paul-J. Lupien, for his outstanding contribution in the field of lipidology. As specialist in laboratory medicine and lipidology, he supervises the CHU de Québec – Laval University clinical lipid laboratory performing lipoprotein, lipid and gene analyses.

 

Interest in clinical research

During his career, he has been dedicated to a better understanding of clinical and biological expressions of primary and secondary hyperlipidemia. He has also participated in the development and application of up to date lipid guidelines for clinicians and contributed to the characterization of new metabolic markers related to atherosclerosis and heart disease. He participated to numerous clinical trials using statins and new emergent therapies in lipoprotein metabolism.

 

Actual clinical research

More recently, he is involved in research on statin-generated myopathy, including identification of blood or genetic markers related to statin side effect and development of clinical tools for a better support to patients suffering from this condition. He is involved in the Canadian Familial Hypercholesterolemia registry. Finally, he is principal investigator in several clinical trials using PCSK9 inhibitors, anti-sense oligonucleotides, ANGPTL-3 inhibitors, and in some cases, gene therapy for very severe hypercholesterolemia or patients at very high CV risk for premature atherosclerotic heart disease.

 

CHUL
2705, boulevard Laurier
C-00-224
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

219 entries « 1 of 22 »

Muller-Wieland D, Rader DJ, Moriarty PM, Bergeron J, Langslet G, Ray KK, Manvelian G, Thompson D, Bujas-Bobanovic M, Roth EM

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.

Journal Article

J Clin Endocrinol Metab, 104 (11), pp. 5253-5262, 2019, ISSN: 0021-972X.

Abstract | Links:

Banerjee A, Alothman L, Couture P, Bergeron J, Belanger AM, Ruel I, Genest J

The Lifelong Burden of Homozygous Familial Hypercholesterolemia.

Journal Article

Can J Cardiol, 35 (10), pp. 1419.e1-1419.e4, 2019, ISSN: 0828-282X.

Abstract | Links:

Maltais A, Lemieux I, Almeras N, Tremblay A, Bergeron J, Poirier P, Despres JP

One-Year Lifestyle Intervention, Muscle Lipids, and Cardiometabolic Risk.

Journal Article

Med Sci Sports Exerc, 51 (10), pp. 2156-2165, 2019, ISSN: 0195-9131.

Abstract | Links:

Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L, Bruckert E

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

Journal Article

N Engl J Med, 381 (6), pp. 531-542, 2019, ISSN: 0028-4793.

Abstract | Links:

Lemieux P, Weisnagel JS, Caron AZ, Julien AS, Morisset AS, Carreau AM, Poirier J, Tchernof A, Robitaille J, Bergeron J, Marette A, Vohl MC, Gagnon C

Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomized, placebo-controlled trial.

Journal Article

Eur J Endocrinol, 2019, ISSN: 0804-4643.

Abstract | Links:

Gangloff A, Bergeron J, Lemieux I, Tremblay A, Poirier P, Almeras N, Despres JP

Relationships between circulating 25(OH) vitamin D, leptin levels and visceral adipose tissue volume: results from a 1-year lifestyle intervention program in men with visceral obesity.

Journal Article

Int J Obes (Lond), 2019, ISSN: 0307-0565.

Abstract | Links:

Carter S, Lemieux I, Li Z, Almeras N, Tremblay A, Bergeron J, Poirier P, Despres JP, Picard F

Changes in IGFBP-2 levels following a one-year lifestyle modification program are independently related to improvements in plasma apo B and LDL apo B levels.

Journal Article

Atherosclerosis, 281 , pp. 89-97, 2019, ISSN: 0021-9150.

Abstract | Links:

Boyer M, Mitchell PL, Poirier DP, Almeras N, Tremblay A, Bergeron J, Despres JP, Arsenault BJ

Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia.

Journal Article

Am J Physiol Endocrinol Metab, 315 (4), pp. E460-E468, 2018, ISSN: 0193-1849.

Abstract | Links:

Marchand GB, Carreau AM, Weisnagel SJ, Bergeron J, Labrie F, Lemieux S, Tchernof A

Increased body fat mass explains the positive association between circulating estradiol and insulin resistance in postmenopausal women.

Journal Article

Am J Physiol Endocrinol Metab, 314 (5), pp. E448-E456, 2018, ISSN: 0193-1849.

Abstract | Links:

Drouin-Chartier JP, Tremblay AJ, Bergeron J, Laflamme N, Lamarche B, Couture P

Impact of lipoprotein apheresis with dextran-sulfate adsorption on the expression of genes involved in cardiovascular health in the blood of patients with homozygous familial hypercholesterolemia.

Journal Article

J Clin Apher, 33 (1), pp. 104-107, 2018, ISSN: 0733-2459.

Abstract | Links:

219 entries « 1 of 22 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
Data provided by the Université Laval research projects registery